XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
Status:
Completed
Trial end date:
2020-09-04
Target enrollment:
Participant gender:
Summary
XIENCE 90 study is a prospective, single arm, multi-center, open label trial to evaluate the
safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR)
undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family of
coronary drug-eluting stents.
The XIENCE family stent systems include commercially approved XIENCE Xpedition Everolimus
Eluting Coronary Stent System (EECSS), XIENCE Alpine EECSS, XIENCE PRO^X EECSS [rebrand of
the XIENCE Xpedition Stent System and is only available outside of the United States (OUS)],
XIENCE PRO^A EECSS (rebrand of the XIENCE Alpine Stent System and is only available OUS) and
XIENCE Sierra EECSS of coronary drug-eluting stents.